TITLE

Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus

AUTHOR(S)
Kolodka, Tadeusz; Charles, Matthew L.; Raghavan, Arvind; Radichev, Ilian A.; Amatya, Christina; Ellefson, Jacob; Savinov, Alexei Y.; Nag, Abhijeet; Williams, Mark S.; Robbins, Mark S.
PUB. DATE
August 2014
SOURCE
PLoS ONE;Aug2014, Vol. 9 Issue 8, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Modulation of the kallikrein-kinin system (KKS) has been shown to have beneficial effects on glucose homeostasis and several other physiological responses relevant to the progression of type 2 diabetes mellitus (T2D). The importance of bradykinin and its receptors in mediating these responses is well documented, but the role of tissue kallikrein-1, the protease that generates bradykinin insitu, is much less understood. We developed and tested DM199, recombinant human tissue kallikrein-1 protein (rhKLK-1), as a potential novel therapeutic for T2D. Hyperinsulinemic-euglycemic clamp studies suggest that DM199 increases whole body glucose disposal in non-diabetic rats. Single-dose administration of DM199 in obese db/db mice and ZDF rats, showed an acute, dose-dependent improvement in whole-body glucose utilization. Sub-acute dosing for a week in ZDF rats improved glucose utilization, with a concomitant rise in fasting insulin levels and HOMA1-%B scores. After cessation of sub-acute dosing, fasting blood glucose levels were significantly lower in ZDF rats during a drug wash-out period. Our studies show for the first time that DM199 administration results in acute anti-hyperglycemic effects in several preclinical models, and demonstrate the potential for further development of DM199 as a novel therapeutic for T2D.
ACCESSION #
97801306

 

Related Articles

  • The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. Schmaier, Alvin H. // Journal of Clinical Investigation;4/15/2002, Vol. 109 Issue 8, p1007 

    Reveals that activation of Hageman factor XII in glass tubes promotes thrombin formation. Mechanisms of kallikrein-kinin system (KKS) activation; KKS in thrombosis; Evidence for the physiologic activities of the KKS.

  • Pathophysiological activities of the kallikrein-kini system with emphasis on the cardiovascular disorders. Sharma, Jagdish N.; Zubaid, Mohammad; Khan, B. Zailina S.J.; Yusof, A. Pauzi M.; Asmawi, M. Zaini // Inflammopharmacology;2000, Vol. 8 Issue 3, p219 

    Reviews the function of the kallikrein-kinin system (KKS) with respect to disease etiology. Potential of bradykinin receptor antagonists and KKS components as novel and versatile therapeutic agents; Kinin forming and inactivating pathways; Kinin receptors and their antagonists; Mode of action...

  • Bioregulation of kinins and cytokines in health and disease. Bhoola, K.D. // South African Journal of Science;Feb97, Vol. 93 Issue 2, p57 

    Focuses on kallikreins and its role in the bioregulation of kinins and cytokines. Physiological roles of kinins and cytokinins; Implication of kinins and cytokines in rheumatoid and osteoarthritis; Sources of kallikrein. INSET: Untitled (kinins research at University of Natal), by K.D.B..

  • Kallikrein-kinin system in postgastrectomy dumping syndrome. Wong, Patrick; Talamo, Richard; Babior, Bernard; Raymond, Guy; Colman, Robert; Wong, P Y; Talamo, R C; Babior, B M; Raymond, G G; Colman, R W // Annals of Internal Medicine;May74, Vol. 80 Issue 5, p577 

    Presents a study which investigated the mechanism of kinin release and the possible relation between kinins and the clinical features of the dumping syndrome. Tissue sources of kallikrein; Mechanism of action of bradykinin; Study plan and clinical observations.

  • You Be the Coder.  // Internal Medicine Coding Alert;Nov2010, Vol. 13 Issue 11, p84 

    The article provides an answer to a question on the calculation of the medications CR Bicillin and Rocephin for tonsillitis.

  • Enfuvirtide has new instructions.  // AIDS Alert;Apr2007, Vol. 22 Issue 4, p44 

    The article reports on the changes made to the instructions in administering enfuvirtide (Fuzeon) distributed by Roche Pharmaceuticals in the U.S.

  • ED.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p723 

    Definitions of the acronym "ED," one of which is effective dose, are presented.

  • ED50.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p723 

    A definition of the term "ED50," which refers to the median effective dose, is presented.

  • F.D.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p853 

    An encyclopedia entry for F.D. which stands for fatal dose is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics